No, Trelegy Ellipta is NOT a metered-dose inhaler (MDI)
Trelegy Ellipta is a dry powder inhaler (DPI), specifically delivered via the ELLIPTA device, not an MDI. 1
Device Type and Mechanism
Trelegy Ellipta is explicitly described as "an inhalation powder drug product" that contains two foil blister strips within a light grey and beige plastic inhaler 1. The medication is delivered as a dry powder that requires the patient to generate sufficient inspiratory flow to:
- Activate the device and expose the powder from both blisters
- Disperse the powder into the airstream created by inhalation through the mouthpiece
- Achieve adequate deaggregation for lung deposition 1, 2
Key Distinguishing Features from MDIs
The ELLIPTA is fundamentally different from MDIs in several ways:
- No propellant: Unlike MDIs which use pressurized propellants to deliver medication, the ELLIPTA relies entirely on patient inspiratory effort 1
- Powder formulation: Contains micronized powder blends with lactose monohydrate as a carrier, not a liquid suspension or solution 1
- Flow-dependent delivery: Requires inspiratory flow rates (typically 30-90 L/min) to achieve optimal dose delivery, whereas MDIs are breath-actuated or require coordination 2
Clinical Performance Data
Research demonstrates that the ELLIPTA DPI delivers >80% of the nominal blister content across flow rates of 30-90 L/min 2. In patients with very severe COPD, mean peak inspiratory flow was 65.8 L/min (range: 43.5-94.1 L/min), and in severe asthma patients it was 96.6 L/min (range: 72.4-124.6 L/min) 1. These flow rates are sufficient for effective drug delivery from this DPI device.
Important clinical note: Dose emission profiles show that near-complete dose delivery occurs rapidly, before reaching peak inspiratory flow 2, meaning patients with compromised lung function can still achieve adequate drug delivery from this DPI.
Practical Implications
This distinction matters clinically because:
- Patients must be counseled on proper DPI technique (different from MDI technique)
- No spacer device is needed or compatible with this device
- Patients with very low inspiratory capacity may theoretically have reduced drug delivery, though studies show adequate delivery even in severe COPD 2
- The device contains milk proteins (lactose carrier), which is a contraindication in patients with severe milk protein hypersensitivity 1